Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 617 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Lung Diseases, Interstitial Clear all

Conditions: Langerhans Cell Histiocytosis
Interventions: GSK2110183; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 2 more

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Blood draw, Questionnaire; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Belumosudil, BSC; Drug · Other
Lead sponsor: Kadmon Corporation, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 10
States / cities: Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 7 more

Conditions: Rejection Chronic Renal
Interventions: Belumosudil 200 mg QD, Placebo; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension, Pulmonary, Lung Diseases, Interstitial
Interventions: TX000045; Drug
Lead sponsor: Tectonic Operating Company, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • San Francisco, California • Boise, Idaho + 1 more

Conditions: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, Histiocytic Disorders
Interventions: F-choline PET Scan, FDG-PET, biopsy; Radiation · Device · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: Trametinib, Dabrafenib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 10
States / cities: Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Interventions: IFX-1 low dose, IFX-1 high dose, Placebo; Drug
Lead sponsor: InflaRx GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 33
States / cities: Scottsdale, Arizona • Loma Linda, California • Doral, Florida + 30 more

Conditions: Interstitial Lung Disease
Interventions: Chest CT, Pulmonary Function Testing; Device · Diagnostic Test
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Pulmonary Fibrosis
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Interstitial Lung Disease, Pulmonary Fibrosis
Interventions: [68Ga]CBP8, Gadoterate Meglumine; Drug
Lead sponsor: Peter Caravan; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Interstitial Lung Disease
Interventions: Blood Gas, Pulmonary Exercise Test, Spirometry, Breath Condensate Collector; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: INS018_055, Placebo; Drug
Lead sponsor: InSilico Medicine Hong Kong Limited; Industry
Eligibility: 40 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 8 more

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: BG00011, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 10
States / cities: San Francisco, California • Atlanta, Georgia • Kansas City, Kansas + 6 more

Conditions: Sarcoidosis, Pulmonary
Interventions: Acthar Gel, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 26 more

Conditions: IPF, Pulmonary Fibrosis, ILD
Interventions: Sample collection, Questionnaires, High resolution CT scan of the chest, Pulmonary Function Test; Other · Radiation · Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 75 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Granulomatosis With Polyangiitis, Wegener Granulomatosis, Vasculitis
Interventions: 5 mg prednisone, 0 mg prednisone; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Granulomatosis With Polyangiitis
Interventions: Rituximab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 6
States / cities: Louisville, Kentucky • Hackensack, New Jersey • New York, New York + 3 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 12 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 33
States / cities: Downey, California • Long Beach, California • Los Angeles, California + 18 more

Conditions: Langerhans Cell Histiocytosis
Interventions: Cytarabine, Vinblastine/prednisone; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 21 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 11
States / cities: Palo Alto, California • San Diego, California • Minneapolis, Minnesota + 8 more

Conditions: Hermansky Pudlak Syndrome, Interstitial Lung Disease
Interventions: Pirfenidone; Drug
Lead sponsor: Jesse Roman; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Interventions: SC291; Biological
Lead sponsor: Sana Biotechnology; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more

Conditions: Vasculitis, Wegener's Granulomatosis
Interventions: Mycophenolate Mofetil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pneumocystis Carinii Pneumonia
Interventions: Antibiotics only, Antibiotics + Corticosteroids, Corticosteroids + antibiotics; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis

The Genetics of Pulmonary Fibrosis

A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis

Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

Assessment of Lung Movement With Computed Tomography (CT)

Dyspnea in Patients With Pulmonary Fibrosis

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

Biomarkers in the Evaluation of Chronic Lung Disease

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Acthar Gel in Participants With Pulmonary Sarcoidosis

Advancing Prevention of Pulmonary Fibrosis

The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

The Safety and Effectiveness of Zidovudine in the Treatment of HIV-Infected Children With Mild to Moderate Symptoms

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

Efficacy and Safety of Pirfenidone Treatment in HPS-ILD

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes

Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)